TCR2 Therapeutics Inc.
TCRRDelisted Jun 1, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750019
TCR2 Therapeutics Inc. was delisted on Jun 1, 2023; its insiders filed their last Form 4 on Feb 14, 2024; 59 institutions reported holding it in 13F filings for Q1 2023, worth $31.5M in total; no superinvestor held it.
Q1 2023 vs. Q4 2022
How the institutions holding TCR2 Therapeutics Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 63 | 59 | −4 |
| Shares | 21.2M | 21.0M | −208.4K (−1.0%) |
| Value | $21.2M | $31.5M | +$10.3M (+48.7%) |
New holders (7)
Institutions that held TCR2 Therapeutics Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Long Focus Capital Management, LLC | 566,270 | $849.4K | 0.14% |
| Sagefield Capital LP | 43,900 | $65.8K | 0.02% |
| Gsa Capital Partners LLP | 37,452 | $56.0K | 0.01% |
| Charles Schwab Investment Management Inc | 22,638 | $34.0K | 0.00% |
| Simplex Trading, LLC | 1,444 | $2.00K | 0.00% |
| Group One Trading, L.P. | 800 | $1.20K | 0.00% |
| UBS Group AG | 234 | $351 | 0.00% |
Sold out (11)
Institutions that held TCR2 Therapeutics Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Citadel Advisors LLC | 233,876 | $233.6K |
| Oasis Management Co Ltd. | 200,000 | $199.8K |
| Kennedy Capital Management, Inc. | 120,389 | $120.2K |
| Victory Capital Management Inc | 74,297 | $74.2K |
| Jane Street Group, LLC | 41,295 | $41.2K |
| Occudo Quantitative Strategies LP | 32,803 | $32.8K |
| Belvedere Trading LLC | 31,992 | $32.0K |
| Schonfeld Strategic Advisors LLC | 26,600 | $26.6K |
| Virtu Financial LLC | 19,204 | $19.0K |
| Belpointe Asset Management LLC | 2,147 | $2.14K |
| GWM Advisors LLC | 47 | $47 |